NCT06828874 is a Phase 4 clinical trial of Levornidazole Disodium Phosphate for Injection in Intraabdominal Infections, sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd.

Who is sponsoring NCT06828874?

NCT06828874 is sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd.

What drugs are being tested in NCT06828874?

Interventions in NCT06828874: Levornidazole Disodium Phosphate for Injection, Ornidazole and Sodium Chloride Injection.

What condition does NCT06828874 study?

NCT06828874 studies Intraabdominal Infections.

Is NCT06828874 still recruiting?

NCT06828874 is currently completed. Last updated 18 February 2025.

Last reviewed 2025-02-18 · How we verify

NCT06828874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria

Completed Phase 4 Last updated 18 February 2025

What this trial tests

Phase 4 trial testing Levornidazole Disodium Phosphate for Injection in Intraabdominal Infections in 696 participants. Completed in 14 October 2024.

Timeline

10 May 2023

Primary endpoint
23 September 2024

14 October 2024

Quick facts

Lead sponsor	Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	696
Start date	10 May 2023
Primary completion	23 September 2024
Estimated completion	14 October 2024
Sites	32 locations across China

Drugs / interventions tested

Levornidazole Disodium Phosphate for Injection — full drug profile →
Ornidazole and Sodium Chloride Injection — full drug profile →

Conditions studied

Intraabdominal Infections — all drugs for Intraabdominal Infections →

Sponsor

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with Intraabdominal Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anaerobic infections are very common in clinical practice. Poor control of anaerobic infections in patients undergoing abdominal surgery may lead to the occurrence of complications. The aim of this study is to explore the efficacy and safety of Levornidazole Phosphate Disodium for Injection in the treatment of patients with postoperative intra-abdominal infections caused by anaerobic bacteria.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of levornidazole disodium phosphate injection in patients with intra-abdominal infections caused by anaerobic bacteria: a multicenter, randomized, single-blind, phase IV, non-inferiority trial (ANAEROGUARD study).
Chen L, Zhang L, Chen R, Zheng Z, et al · · 2026 · PMID 41761107 · DOI 10.1186/s12879-026-12789-7

Verify or expand the search:

Other trials of Levornidazole Disodium Phosphate for Injection

Trials testing the same drug.

NCT07033182 — Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment an · Phase 1 · completed

Other recruiting trials for Intraabdominal Infections

Currently open trials in the same condition.

NCT03482245 — The Role of Circadian Clock Proteins in Innate and Adaptive Immunity · NA · recruiting

Other Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd trials

Trials by the same sponsor.

NCT06902103 — Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy · Phase 1 · completed
NCT07033182 — Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment an · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06828874 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Last refreshed: 18 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06828874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing